Erlotinib regulates short-term memory, tau/Aβ pathology, and astrogliosis in mouse models of AD
IntroductionErlotinib is an epidermal growth factor receptor (EGFR) inhibitor that is approved by the FDA to treat non-small cell lung cancer (NSCLC). Several membrane receptors, including EGFR, interact with amyloid β (Aβ), raising the possibility tha…